Pure Global
NCT04684992

GEBT Telehealth Administration Usability Study

Telehealth Administration of 13C-Spirulina Gastric Emptying Breath Test (13C-GEBT) Usability Study
Cairn Diagnostics·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Gastroparesis
Drug/Device/Intervention
GEBT Telehealth Administration Usability
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Cairn Diagnostics
Location
Brentwood, United States of America
Timeline & enrollment
Phase
N/A
Start date
Dec 11, 2020
End date
Mar 10, 2021
Enrollment
36 participants
Primary outcome

Patient Ability to Prepare and Administer the 13C-Spirulina GEBT, Under the Supervision of a Telehealth Professional, According to Instructions,Patient Ability to Prepare and Administer the 13C-Spirulina GEBT, Under the Supervision of a Telehealth Professional, According to Instructions,Patient Ability to Complete the GEBT Test Request Form, Under the Supervision of a Telehealth Professional, According to the Instructions,Patient Ability to Complete the GEBT Test Request Form, Under the Supervision of a Telehealth Professional, According to the Instructions,Patient Ability to Collect GEBT Breath Samples Under the Supervision of a Telehealth Professional,Ability to Successfully Ship Kits/Breath Samples to/From Home,Ability of a Telehealth Platform to Function Correctly,Ability of a Telehealth Platform to Function Correctly,Safety of Telehealth Administration of 13C-Spirulina GEBT Versus Administration in a Clinician's Facility

Summary

The purpose of this study is to establish the usability of a telehealth platform for the
 administration of GEBT.

ICD-10 classifications
Attention to gastrostomyGastrostomy statusOther gastritisGastritis, unspecifiedGastric diverticulum
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04684992
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT04684992 through Pure Global AI's free database. This phase not specified trial is sponsored by Cairn Diagnostics and is currently Completed. The study focuses on Gastroparesis. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.